Xilio Therapeutics (NASDAQ:XLO) Upgraded by Wall Street Zen to “Buy” Rating

Wall Street Zen upgraded shares of Xilio Therapeutics (NASDAQ:XLO) from a hold rating to a buy rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xilio Therapeutics in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $28.00.

Xilio Therapeutics Stock Down 4.1%

Shares of XLO stock opened at $8.32 on Friday. Xilio Therapeutics has a 12-month low of $6.47 and a 12-month high of $16.52. The company has a market capitalization of $48.09 million, a PE ratio of -1.51 and a beta of -0.05. The firm has a 50 day moving average price of $7.96 and a two-hundred day moving average price of $9.56.

Xilio Therapeutics (NASDAQ:XLO) last posted its earnings results on Monday, March 23rd. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.68) by $0.83. The company had revenue of $13.69 million for the quarter, compared to the consensus estimate of $10.90 million. Xilio Therapeutics had a negative return on equity of 393.01% and a negative net margin of 80.05%. As a group, research analysts expect that Xilio Therapeutics will post -1.14 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. State Street Corp raised its position in shares of Xilio Therapeutics by 13.7% in the fourth quarter. State Street Corp now owns 186,390 shares of the company’s stock valued at $119,000 after buying an additional 22,500 shares in the last quarter. Jane Street Group LLC acquired a new stake in Xilio Therapeutics during the fourth quarter worth approximately $27,000. Squarepoint Ops LLC grew its position in Xilio Therapeutics by 39.6% during the third quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock worth $277,000 after buying an additional 93,338 shares in the last quarter. Renaissance Technologies LLC increased its stake in Xilio Therapeutics by 68.3% during the 4th quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock worth $220,000 after acquiring an additional 139,716 shares during the period. Finally, Velan Capital Investment Management LP bought a new position in Xilio Therapeutics during the 4th quarter worth $109,000. 54.29% of the stock is owned by institutional investors.

About Xilio Therapeutics

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.